ORG-129

DRUG2 trials

Sponsors

Agomab Spain S.L.U., Origo Biopharma

Conditions

Fibrostenotic Crohn’s DiseaseHealthy Volunteers

Phase 1

First in Human Study of ORG-129 in Healthy Volunteers

CompletedNCT04933565

Origo BiopharmaHealthy Volunteers

Start: 2021-06-01End: 2023-01-09Updated: 2023-01-17

Phase 2

A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients with Fibrostenotic Crohn’s Disease

Active, not recruitingCTIS2022-502789-26-01

Agomab Spain S.L.U.Fibrostenotic Crohn’s Disease

Start: 2023-11-03Target: 63Updated: 2026-01-09